Furthermore, regarding pancreatic cancer, HDAC6 inhibition cooperates with the gemcitabine, showing strong potent anticancer effects both in vitro and in vivo, which suggests that targeting HDAC6 is a therapeutic option for pancreatic cancer. Here, HDAC6 is linked to familial pancreatic carcinoma.